
Larry Anderson, M.D., Ph.D.
Associate Professor
Department Internal Medicine
You have reached the Academic Profile.
For more information on the doctor and patient care, please visit the clinical profile.
View Clinical Profile
Education
- Medical School
- UT Health Science Center McGovern Medical School (2000)
- Internship
- Mayo Clinic (2003), Internal Medicine
- Fellowship
- Fred Hutchinson Cancer Research Center (2006), Medical Oncology
Research Interest
- Cancer immunology
- CAR T-Cells
- Immunotherapy
- MAGE-C1 (CT-7)
- Multiple Myeloma
- Stem Cell Transplantation
Publications
Featured Publications
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
- Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, Moreau P, Yakoub-Agha I, Delforge M, Cavo M, Einsele H, Goldschmidt H, Weisel K, Rambaldi A, Reece D, Petrocca F, Massaro M, Connarn JN, Kaiser S, Patel P, Huang L, Campbell TB, Hege K, San-Miguel J, N Engl J Med 2021 02 384 8 705-716
- Nonmyeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenstrom macroglobulinemia: Evidence for a graft-versus-lymphoma effect.
- Maffini E, Anderson LD, Sandmaier BM, Green DJ, Storer BE, Niederwieser D, Maziarz RT, Maloney DG, Storb R Haematologica 2018 Mar
- Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma.
- Anderson LD, Cook DR, Yamamoto TN, Berger C, Maloney DG, Riddell SR Cancer Immunol. Immunother. 2011 Jul 60 7 985-97
- Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of Multiple Myeloma
- Anderson LD Jr, Cook DR, Yamamoto T, Berger C, Maloney DG, and Riddell SR Cancer Immunology Immunotherapy 2011 (In Press)
- Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease
- Anderson LD Jr, Savary CA, and CA Mullen Blood April 2000 95 2426-2433
- The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement.
- Bergstrom CP, Dahiya S, Chen W, Zhang CC, Zhu H, Yan J, Madanat Y, Patel P, Vusirkala M, Ramakrishnan P, Rizvi S, Chung S, Awan F, Anderson LD, Collins R, Kansagra A, Leuk Res 2020 Nov 100 106480
- Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
- Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, Pylypenko H, Auner HW, Leleu X, Doronin V, Usenko G, Bahlis NJ, Hajek R, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Gironella M, Jurczyszyn A, Robak P, Galli M, Wallington-Beddoe C, Radinoff A, Salogub G, Stevens DA, Basu S, Liberati AM, Quach H, Goranova-Marinova VS, Bila J, Katodritou E, Oliynyk H, Korenkova S, Kumar J, Jagannath S, Moreau P, Levy M, White D, Gatt ME, Facon T, Mateos MV, Cavo M, Reece D, Anderson LD, Saint-Martin JR, Jeha J, Joshi AA, Chai Y, Li L, Peddagali V, Arazy M, Shah J, Shacham S, Kauffman MG, Dimopoulos MA, Richardson PG, Delimpasi S, Lancet 2020 11 396 10262 1563-1573
- Lenalidomide-Associated Secondary B-Lymphoblastic Leukemia/Lymphoma-A Unique Entity.
- Germans SK, Kulak O, Koduru P, Oliver D, Gagan J, Patel P, Anderson LD, Fuda FS, Chen W, Jaso JM, Am J Clin Pathol 2020 11 154 6 816-827
- Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.
- Dimopoulos M, Weisel K, Moreau P, Anderson LD, White D, San-Miguel J, Sonneveld P, Engelhardt M, Jenner M, Corso A, Dürig J, Pavic M, Salomo M, Casal E, Srinivasan S, Yu X, Nguyen TV, Biyukov T, Peluso T, Richardson P, Leukemia 2020 Sep
- Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.
- Chari A, Cornell RF, Gasparetto C, Karanes C, Matous JV, Niesvizky R, Lunning M, Usmani SZ, Anderson LD, Chhabra S, Girnius S, Shustik C, Stuart R, Lee Y, Salman Z, Liu E, Valent J, Hematol Oncol 2020 Aug 38 3 353-362
Honors & Awards
- Elected as a Fellow of the American College of Physicians
FACP (2021) - Texas Super Doctor
(2018-2020) - Leukemia & Lymphoma Society North Texas Man of the Year
(2015) - Texas Super Doctor Rising Star
(2013-2014) - ACS Institutional Research Grant
Research Grant (2010) - ASCO Young Investigator Award
Research Grant (2006) - K12 Career Development Award
Research Grant (2006) - Multiple Myeloma Research Foundation Fellow Award
Research Grant (2006)
Professional Associations/Affiliations
- American Society of Clinical Oncology (2017)
- American Society for Transplantation and Cellular Therapy (2014)
- American College of Physicians (2013)
- American Society of Hematology